In 2025, iSpace in Tokyo will attempt its Venture Moon mission, carrying a lander and micro rover. Intuitive Machines in the US will send a Falcon 9 rocket with a lander carrying NASA's ice trail and a mass spectrometer to the Moon's south pole. NASA's Lunar Trailblazer will orbit the Moon to map water on its surface.
NASA's PUNCH mission, consisting of four satellites, will capture 3D images of the Sun's atmosphere to study how energy and mass become the solar wind, a phenomenon that has puzzled astronomers for 60 years.
The SMILE mission, a collaboration between the European Space Agency and the Chinese Academy of Sciences, will study how solar wind interacts with Earth's magnetic field.
The NASA-ISRO Synthetic Aperture Radar mission will map nearly all of Earth's land and ice-covered surfaces twice every 12 days, providing crucial data for researchers studying the planet's state.
The Biomass Space mission, led by the European Space Agency, will use radar to measure forest biomass and its role in the carbon cycle, aiding climate scientists in studying deforestation.
COP 30 in Belem, Brazil, will address unresolved decisions from COP 29, including how $300 billion in annual climate finance for developing countries will be delivered, whether as grants or loans, and the balance between private and public sector contributions.
Researchers worry that Donald Trump may pull the US out of the Paris Agreement again, which commits countries to limit global warming to 1.5-2°C above pre-industrial levels, as he did in 2019.
Robert Kennedy Jr., a vaccine sceptic, could impact public health policies and research, raising concerns among scientists about the future of public health initiatives.
In 2025, Eli Lilly will complete a phase 3 trial for Orfogliprone, an oral, non-peptide GLP-1 agonist, while Emgen prepares a phase 3 trial for Maritide, a double-action drug targeting blood sugar control and metabolism. These drugs may also be explored for treating conditions like Alzheimer's, Parkinson's, addiction, and smoking.
The European Spallation Source in Sweden, a massive neutron beam machine, will partially operate in 2025, firing a proton beam at a heavy metal target to generate neutron beams for studying condensed matter, magnetic materials, and material structures.
CERN is completing a feasibility study in 2025 for the Future Circular Collider, a 91-kilometre ring-shaped particle accelerator, to evaluate its financial viability, technical aspects, and environmental impacts before making a final decision in 2028.
The FDA is reviewing suzitrogen, a non-opioid painkiller developed by Vertix Pharmaceuticals, in January 2025. If approved, it will be the first new class of drugs to treat acute pain in over 20 years.
In this episode, reporter Miryam Naddaf joins us to talk about the big science events to look out for in 2025. We’ll hear about: the latest Moon missions, 30 years of the United Nations' COP climate summits, the return of Donald Trump, and more.
Nature: Science in 2025: the events to watch for in the coming year) Hosted on Acast. See acast.com/privacy) for more information.